Table 2.

Frequency of antiretroviral drug use and viral suppression at screening and at 12 months by study site

	Kisumu, Kenya (N = 14)	Blantyre, Malawi (N = 14)	Cape Town, South Africa (N = 16)	Soweto, South Africa (N = 20)
ARV drug use
ARV drug use at screening	9/14 (64.3%)	2/14 (14.3%)	6/16 (37.5%)	1/20 (5.0%)
ARV drug use at 12 months	11/14 (78.6%)	7/14 (50.0%)	9/16 (56.3%)	11/20 (55.0%)
Increase in ARV drug use	1.2-fold	3.5-fold	1.5-fold	11-fold
Viral suppression
Virally suppressed at screening	7/14 (50.0%)	2/14 (14.3%)	3/16 (18.8%)	2/20 (10.0%)
Virally suppressed at 12 months	11/14 (78.6%)	6/14 (42.9%)	7/16 (43.8%)	13/20 (65.0%)
Increase in viral suppression	1.6-fold	3.0-fold	2.3-fold	6.5-fold

The table shows the frequency of ARV drug use and viral suppression at screening and 12 months at each of the four study sites. The fold change increase in ARV drug use and viral suppression during the 12-month follow-up period is also shown.

Abbreviations: ARV, antiretroviral.